Evidence map›Paper›PMID 32946567›Full record

ArticleBlood advances2020

Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib.

Paul J Hampel, Hua-Jay J Cherng, Timothy G Call, Wei Ding, Mahsa Khanlari, Ellen D McPhail, Roberto N Miranda, Pei Lin, Hussein A Tawbi, Alessandra Ferrajoli and 3 more

Abstract read
In one paragraph

Article in Blood advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. A Case of Pseudo-Richter Transformation Following Zanubrutinib Discontinuation in CLL.Mediterranean journal of hematology and infectious diseases · 2026
    Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. An Approach to Diagnosis of Richter Transformation in Chronic Lymphocytic Leukemia.Journal of the advanced practitioner in oncology · 2022
    Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Paul J HampelDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
Hua-Jay J CherngDepartment of Leukemia and.
Timothy G CallDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
Wei DingDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
Mahsa KhanlariDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Ellen D McPhailDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; and.
Roberto N MirandaDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Pei LinDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Hussein A TawbiDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Alessandra FerrajoliDepartment of Leukemia and.
William G WierdaDepartment of Leukemia and.
Nitin JainDepartment of Leukemia and.
Sameer A ParikhDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Large B-Cell, DiffuseAdenineHumansPiperidinesPyrazolesPyrimidinesAdenineibrutinibPiperidinesPyrazolesPyrimidines

Identifiers

PMID32946567
PMCPMC7509865

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.